The Clover Health decision didn’t just trigger a recalculation of Star Ratings and Quality Bonus Payments — it challenged CMS’s authority to include certain measures in the program at all. That’s a fundamentally different kind of disruption than a routine methodology update, and CMS has yet to provide definitive guidance on how the affected measures will be treated in future years. For Medicare Advantage organizations, that uncertainty isn’t a reason to wait. Plans are still making decisions this quarter on bids, quality investments, care management programs, pharmacy strategy, and product design — and the organizations that come out ahead won’t be the ones who benefited most from this recalculation. They’ll be the ones who used this moment to reassess long-held assumptions and build real strategic flexibility.
This webinar focuses on what health plans should be evaluating right now — grounded in four concrete areas of action:
- Modeling future-state Stars scenarios, including what happens if affected measures don’t return
- Reassessing existing quality programs and interventions — especially those built around Part D measures — without overcorrecting
- Identifying which measures (like Transitions of Care, Readmissions, Glycemic Status, and Blood Pressure Control) are likely to remain durable regardless of how CMS restructures the program
Building the underlying organizational capabilities — care coordination, chronic disease management, member engagement — that hold value across multiple regulatory scenarios